Long acting injectables in management of schizophrenia
Starting on:
Dec 11, 2025
Ending on:
Dec 11, 2025
Moderator(s):
Dr. Rajab Saddam
Consultant Psychiatrist, Kenyatta National Hospital, KPA NEC Member
Venue:
Hybrid
Max Credits:
3 Points

Provider:
Kenya Psychiatrists Association
Claim Points

Long acting injectables in management of schizophrenia

Starting on:
Dec 11, 2025
Ending on:
Dec 11, 2025
Venue:
Hybrid

Description

This activity focuses on the role of long-acting injectable (LAI) antipsychotics in the management of schizophrenia, with particular emphasis on real-world clinical experiences and outcomes from patients receiving LAI therapy. Through discussion of practical case examples, the session highlights the place of Paliperidone Palmitate long-acting injection (PPLAI) within current treatment algorithms, including appropriate patient selection, optimal timing, and evidence-based initiation strategies. The activity aims to support clinicians in improving adherence, symptom control, and long-term functional outcomes in patients with schizophrenia.

Objectives

By the end of this activity, participants will be able to: Describe real-world clinical outcomes and practical considerations from patients treated with long-acting injectable antipsychotics. Explain the role of Paliperidone Palmitate LAI within the schizophrenia treatment algorithm. Identify appropriate patient selection criteria for initiation of PPLAI. Determine optimal timing and evidence-based initiation strategies for PPLAI in routine clinical practice. Apply insights from clinical cases to improve adherence, relapse prevention, and overall treatment outcomes in schizophrenia.

Presenters

  1. Dr. Silvia Kemunto
    Consultant Psychiatrist, Founder and CEO of Mental Health Planet

  2. Prof. Hisham Ramy
    Professor of Psychiatry, Institute of Psychiatry, Ain Shams University. Secretary General of Mental Health, Ministry of Health, Egypt, Fully Registered Consultant of Psychiatry, England

Search For CPD Activity